EL PASO, Texas--(BUSINESS WIRE)--Premier Biomedical, Inc.(OTCQB:"BIEI")
a biotech research company focused on discovering, developing, and
commercializing medical treatments for a wide range of diseases in
humans, including innovative therapies for breast cancer, as well as for
neurofibromatosis, atherosclerosis and muscular dystrophy, announced the
filing of a provisional patent on a second drug to treat fibromyalgia,
neuropathic pain, MS symptoms, and alcohol and chemical addiction. This
new drug is in addition to Premier’s existing Feldetrex® drug, to
compete in this segment of the health care market representing an
opportunity of $16B annually.

William A. Hartman, President and CEO of Premier Biomedical stated, “We
are continuing to advance our technology to improve and expand our
healthcare products to help relieve the pain and suffering of patients
afflicted with these diseases and conditions, not only here in the U.S.,
but also in Brazil, Asia and Europe through pending and future joint
ventures.”

Premier
Biomedical, Inc. (OTCQB:BIEI)
is a research-based company that intends to discover and develop medical
treatments for a wide range of diseases in humans. Premier has obtained,
via license agreements, the technology behind multiple provisional
patents in the United States and a PCT Europe National Patent. Founded
in 2010, Premier has partnered with the Department of Defense with
Center of Expertise at the William Beaumont Army Medical Center. The
company's R&D efforts are centered in El Paso, TX. The Company is a
fully-reporting issuer whose common stock trades on the OTCQB
marketplace maintained by OTC Markets Group, Inc. under the ticker
symbol "BIEI".

Certain statements contained herein are “forward-looking statements” (as
defined in the Private Securities Litigation Reform Act of 1995).
Premier Biomedical, Inc. cautions that statements, and assumptions made
in this news release constitute forward-looking statements and makes no
guarantee of future performance. Forward-looking statements are based on
estimates and opinions of management at the time statements are made.
These statements may address issues that involve significant risks,
uncertainties, estimates made by management. Actual results could differ
materially from current projections or implied results. Premier
Biomedical, Inc. undertakes no obligation to revise these statements
following the date of this news release.